Jose Armando Puente

Address:

7159 Western Trl Dr, San Antonio, TX 78244

VIN:

1FTRX12WX7KD09032

Make:

FORD

Model:

F-150

Year:

2007

Address:

7077 Marie Ave, Pensacola, FL 32504

VIN:

JTDBT923671035528

Make:

TOYOTA

Model:

YARIS

Year:

2007

US Patent:

7528247, May 5, 2009

Filed:

Jan 9, 2004

Appl. No.:

10/755005

Inventors:

William E. Bauta - San Antonio TX, US
Brian D. Burke - Lafayette IN, US
Brian E. Schulmeier - San Antonio TX, US
Dennis P. Lovett - San Antonio TX, US
Jose Puente - San Antonio TX, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C07H 19/16
C07H 19/073

US Classification:

536 553, 536 271, 536 273, 536 281

Abstract:

The present invention for the stereoselective preparation of 2-deoxy-β-D-adenine nucleosides wherein a blocked 2-deoxy-α-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative.

US Patent:

7947824, May 24, 2011

Filed:

May 4, 2009

Appl. No.:

12/435326

Inventors:

William E. Bauta - San Antonio TX, US
Brian D. Burke - Lafayette IN, US
Brian E. Schulmeier - San Antonio TX, US
Dennis P. Lovett - San Antonio TX, US
Jose Puente - San Antonio TX, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C07H 19/16
C07H 19/073

US Classification:

536 553, 536 271, 536 273, 536 281

Abstract:

The present invention for the stereoselective preparation of 2-deoxy-β-D-adenine nucleosides wherein a blocked 2-deoxy-α-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative.

US Patent:

20030114663, Jun 19, 2003

Filed:

Aug 1, 2002

Appl. No.:

10/209808

Inventors:

William Bauta - San Antonio TX, US
Brian Burke - Lafayette IN, US
Brian Schulmeier - San Antonio TX, US
William Cantrell - San Antonio TX, US
Dennis Lovett - San Antonio TX, US
Jose Puente - San Antonio TX, US

International Classification:

C07H019/16

US Classification:

536/027300, 536/055300

Abstract:

The present invention provides for the preparation -adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy--D-adenine nucleosides wherein a blocked 2-deoxy--D-arabinofuranosyl halide is coupled with the salt of an adenine derivative. The forgoing aspects of the present invention are utilized in the preparation of a clofarabine composition wherein the ratio of to -anomer is at least 99:1.

US Patent:

20110282045, Nov 17, 2011

Filed:

May 13, 2011

Appl. No.:

13/106950

Inventors:

William E. Bauta - San Antonio TX, US
Brian D. Burke - LaFayette IN, US
Brian E. Schulmeier - San Antonio TX, US
Dennis P. Lovett - San Antonio TX, US
Jose Puente - San Antonio TX, US

International Classification:

C07H 19/19

US Classification:

536 273

Abstract:

The present invention for the stereoselective preparation of 2-deoxy-β-D-adenine nucleosides wherein a blocked 2-deoxy-α-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative.

US Patent:

20130035306, Feb 7, 2013

Filed:

Jul 6, 2012

Appl. No.:

13/543425

Inventors:

William E. Bauta - San Antonio TX, US
Brian D. Burke - Lafayette IN, US
Brian E. Schulmeier - San Antonio TX, US
Dennis P. Lovett - San Antonio TX, US
Jose Puente - San Antonio TX, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 31/7076
A61P 31/12
A61P 35/00

US Classification:

514 45

Abstract:

The present invention provides for the preparation β-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy-β-D-adenine nucleosides wherein a blocked 2-deoxy-α-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative. The forgoing aspects of the present invention are utilized in the preparation of a clofarabine composition wherein the ratio of β to α-anomer is at least 99:1.